Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glavonoid is a standardized licorice flavonoid oil (LFO) derived from the roots of *Glycyrrhiza glabra* (licorice) using a proprietary extraction process. It is primarily composed of oil-soluble prenylflavonoids, with glabridin serving as the major active constituent. While Glavonoid is commercially available as a dietary supplement marketed for the reduction of visceral fat and improvement of metabolic syndrome markers, it is currently being investigated as a therapeutic agent for transthyretin amyloidosis (ATTR). Its mechanism of action in ATTR involves the kinetic stabilization of the transthyretin (TTR) tetramer. By binding to the thyroxine-binding sites of TTR, Glavonoid prevents the dissociation of the tetramer into amyloidogenic monomers, thereby inhibiting the formation of amyloid fibrils. This stabilization approach is intended to slow the progression of amyloid deposition in organs such as the heart and peripheral nerves, particularly in patients who are ineligible for standard-of-care TTR stabilizers or gene silencers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glavonoid.